b r i e f c o m m u n i c at i o n s AAV vectors offer unique advantages over other vector systems in gene therapy applications. Several studies have shown that these replicationdeficient parvovirus vectors can deliver DNA to specific tissues and confer long-term transgene expression in a variety of systems 1, 2 . Although many studies have looked at the tissue-specific expression elicited by each of the AAV serotypes 3 , a true understanding of how AAV transduces these tissues is still unclear. Of the large AAV family, only a few receptors or co-receptors have been identified for any of the parvoviruses 4 . The ability to better target transduction to specific tissues on the basis of the receptors that each serotype uses for entry is essential to enable users to pick a serotype given the receptor expression in specific tissue or to exploit altered receptor expression under disease conditions. AAV6 has been reported to effectively transduce muscle 5 , lung 6 , brain 7 and multiple types of tumors, including gliomas 7 and lung adenocarcinomas 8 , and to elicit lower serum-neutralizing antibody concentrations when compared with AAV2 (ref. 9 ). Identifying the receptor and any intracellular signaling pathway used by AAV6 to transduce these tissues would enable further development of this vector for gene therapy applications and may shed light on other similar AAV serotypes, including AAV1, AAV(VR-195) and AAV(VR-355) 10 .
Previously, we have shown the utility of a bioinformatics-based approach, CGA, to identify platelet-derived growth factor receptor as a receptor for AAV5 (ref. 11) . In this study, we added bioinformaticsbased software packages to further prioritize potential AAV cell surface receptors. The expression data and Pearson correlation coefficient (PCC) values were obtained from the Developmental Therapeautics Program online database and web-accessible COMPARE program (Supplementary Methods). Using this refined approach, we identified a positive correlation between EGFR expression (DTP microarray pattern identification number GC16212) and cells permissive to AAV6 (PCC value of 0.421, P = 0.003, Supplementary Fig. 1 ). Although EGFR was not returned with the highest-rank-order PCC value from COMPARE analysis, the extensive clustering of positive PCC genes connected to the EGFR signaling pathway provided a reason to further explore the involvement of EGFR or its downstream signaling pathways in AAV6 transduction.
To test our in silico hypothesis, we measured the influence of EGFR expression on AAV6 transduction. Initially, we engineered 32D cells, an IL-3-dependent hematopoietic progenitor cell line, that lack EGFR expression to stably express EGFR (32D-EGFR) and transduced them with multiple AAV serotypes. Wild-type 32D cells were not permissive for any of the serotypes tested ( Fig. 1a) . In the presence of EGFR, AAV6 was able to efficiently transduce 54.1 ± 0.3% of the 32D-EGFR cells ( Fig. 1a,b ). Like AAV6, AAV1 was able to transduce the 32D-EGFR cells, but to a lesser extent ( Fig. 1a,b ), suggesting additional molecules may be necessary for optimal transduction activity with this vector. The lack of transduction by AAV2 or AAV5 in the presence or absence of EGFR ( Fig. 1a,b ) suggests EGFR specificity for AAV6-like viruses. We next used EGFR-specific siRNA to knock down EGFR expression and evaluated the impact on AAV transduction in two cell lines, HEK293T cells and HN13 cells, human embryonic kidney and head-and-neck tumor cell lines, respectively. In HEK293T and HN13 cells, EGFR expression was knocked down by 37% and 58%, respectively, with EGFR-specific siRNA and, in accordance, corresponded with a 40% and 70% decrease in transduction, respectively ( Fig. 1c) .
To better understand the role of EGFR in AAV6 transduction, we measured AAV6 vector transduction in the presence or absence of the EGFR inhibitors AG1478 or gefitinib. AAV6 transduction of HEK293T cells was inhibited by 50% in the presence of either inhibitor ( Fig. 1d ). Under the same conditions, AAV2 transduction was unchanged ( Fig. 1d) . Further analysis suggested that EGFR is involved in vector entry, as AAV internalization was decreased by over 500% in the presence of gefitinib ( Fig. 1e) . These results suggest that functional signaling through EGFR is required for AAV6 transduction and vector internalization.
Although the above data suggest a direct interaction between EGFR and AAV6, EGFR could be functioning as a part of a complex, or AAV6 could be using the same trafficking pathway as EGFR. To measure direct EGFR-AAV6 interaction, we prebound soluble recombinant Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6
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A key step in gene therapy is the efficient transfer of genes in a cell type-and tissue-specific manner. To better understand the mechanism of adeno-associated virus serotype 6 (AAV6) transduction, we used comparative gene analysis (CGA) combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. Subsequent experiments suggested that EGFR is necessary for vector internalization and probably functions as a co-receptor for AAV6.
human EGFR-Fc fusion protein (rhEGFR-Fc) or soluble FGFR (rhFGFR-Fc) to protein A-sepharose beads and incubated them with AAV2, AAV5 or AAV6. Of the three serotypes used, AAV6 binding increased approximately sevenfold in the presence of rhEGFR-Fc ( Fig. 1f) . We did not observe any significant increase in EGFRspecific binding with AAV2 or AAV5 ( Fig. 1f) . Furthermore, AAV6 did not bind to rhFGFR-Fc-coated beads ( Fig. 1f ), suggesting a specific AAV6-EGFR interaction.
Previous studies have suggested an association between EGFR and intracellular signaling pathways that regulate AAV2 transgene expression 12, 13 . One study showed that by inhibiting EGFR with tyrphostin-23, AAV2 transduction was increased, whereas using AG1478 resulted in no change AAV2 transduction. This is in agreement with our current study, where we found no significant change in AAV2 transduction in the presence of AG1478 (Fig. 1f) . Further research will be required to determine which of the multiple EGFR downstream signaling pathways is regulating AAV6 transduction compared to AAV2 transduction. It is possible that AAV6 has evolved the ability to manipulate intracellular signaling and enhance its infectivity through mechanisms that are distinct from AAV2.
Increased expression of EGFR correlates with aggressive headand-neck squamous cell carcinoma (HNSCC) tumor growth and resistance to treatment 14 . We next assessed the utility of AAV6 to transduce and ablate specific HNSCCs presenting with elevated EGFR expression by gene-directed enzyme prodrug therapy. We selected two HNSCC cell lines, HN12 and HEp-2, to represent polarities of EGFR expression. HN12 cells express a higher level of membrane-localized EGFR compared with HEp-2 cells, which express a lower, more diffuse pattern of EGFR expression 15 . In preliminary in vitro studies, HN12 cells showed an EGFR-dependent AAV6 transduction, whereas HEp-2 cells were markedly less permissive to AAV6, and transduction of HEp-2 cells was not altered in the presence of AG1478 (Supplementary Fig. 2) . To evaluate the AAV6-EGFR interaction in vivo, we developed xenograft tumor models of these two cell lines in female athymic (nu/nu) nude mice and intratumorally injected the tumors with AAV6 containing a luciferase transgene under control of a cytomegalovirus immediate early promoter (AAV6-CMV-Luciferase). Upon receiving an intraperitoneal injection of solution containing luciferin (the chemical substrate for luciferase protein), the HN12 tumors that received AAV6-CMV-luciferase showed a significantly elevated (15-fold) average radiance of 1.01 × 10 4 ± 0.31 × 10 4 photons s −1 cm −2 sr −1 , after subtraction of average background radiance, compared with the Hep-2 tumors (0.69 × 10 3 ± 0.48 × 10 3 photons s −1 cm −2 sr −1 ) ( Fig. 2a) . This difference in transduction activity was also confirmed by quantification of vector genomes isolated from the tumors (Supplementary Fig. 3) . The ability of AAV6 to efficiently transduce EGFR-expressing tumors in vivo presented an opportunity to target and deliver cytotoxic transgenes to HN12 tumors highly expressing membrane-localized EGFR.
To test whether the specificity and tropism of AAV6 for EGFRexpressing HN12 cells was sufficient to ablate tumor growth without damaging the surrounding EGFR-expressing muscle, we injected HN12 xenograft tumors with AAV6 vectors encoding herpes simplex virus thymidine kinase (HSVtk) followed 7 d later by treatment with ganciclovir. At the culmination of the study (day 20), we observed a 65% reduction in tumor growth between tumors transduced with AAV6-CMV-HSVtk vector and treated with ganciclovir and tumors that received only ganciclovir treatment (Fig. 2b) . Although not explored in this study, alternative methods of vector delivery such as convection may enhance AAV6 distribution and, thus, more widespread tumor killing than the simple intratumoral injection tested in this study.
This study presents what is to our knowledge the first evidence that EGFR is a co-receptor for AAV6. The methodology detailed here can be exploited to identify the receptors for other AAV serotypes or other virus families. Although we have identified EGFR as a co-receptor for AAV6, expression of other cell surface molecules, such as intracellular adhesion molecule-1, also positively correlated with AAV6 Control siRNA EGFR siRNA EGFR 0 9,000 8,000 7,000 6,000 5,000 4,000 GFP-positive cells per 10,000 cells Percentage GFP-positive cells relative to control 3,000 2,000 1,000 Figure 2 AAV6 mediated transduction of EGFR expressing tumors and delivery of cytotoxic transgene, HSVtk, followed by ganciclovir treatment results in a significant reduction in tumor growth. (a) Head and neck tumor cell lines, HN12 and HEp-2, were injected subcutaneously into the right and left flank of female nude mice. After tumors were established, AAV6-CMV-luciferase was introduced by direct intratumoral injection to the right flank tumors, with the vehicle control injected into the left flank tumors. Ten days after AAV administration, in vivo luciferase activity was measured by bioluminescence after intraperitoneal injection of luciferin (representative images, n = 5). (b) Percentage growth of HN12 tumors injected with AAV6-CMV-HSVtk followed by ganciclovir (GCV) treatment and HN12 tumors treated with GCV alone. The HN12 xenograft tumors received intratumoral injections of AAV6-CMV-HSVtk. One week after AAV6 transduction, mice were started on daily GCV injections. Arrow indicates day GCV treatment was started. *P < 0.05, **P < 0.001, n = 9. Mice were housed in a pathogen-free facility, and all procedures involving mice were performed in compliance with the NIH Guidelines on Use of Animals in Research and approved by the NIDCR Animal Care and Use Committee.
